The US FDA has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, offering a new alternative to daily insulin injections. Onswik, used alongside diet and exercise, can reduce injection frequency by over 300 times per year compared to daily basal insulin. The approval followed successful late-stage trials with over 3,400 participants, showing Onswik's effectiveness in controlling blood sugar levels. It will be available soon in the US as a pre-filled KwikPen in two concentrations, but is not recommended for type 1 diabetes due to hypoglycemia risks.
As of Sep 25, 2026 00:31 WIB, Eli Lilly And Co (LLY) shares are trading at USD 1,186.75 on Pluang, showing a 1-day gain of 2.95%. The stock sees strong buying interest with 81% of orders on Pluang being buys. Eli Lilly's market cap stands at $1.03 trillion, reflecting its significant presence in the health sector.
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity ...
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despit...
Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition....
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
